Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Aonong Biological Technology Grouporp (SHSE:603363) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Fujian Aonong Biological Technology Grouporp Forward PE Ratio Related Terms
Fujian Aonong Biological Technology Grouporp Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Aonong Biological Technology Grouporp Forward PE Ratio Chart
Fujian Aonong Biological Technology Grouporp Annual Data
Trend
Forward PE Ratio
Fujian Aonong Biological Technology Grouporp Quarterly Data
Forward PE Ratio
SHSE:603363 vs ADM, BG, TSN: Forward PE Ratio Comparison
For the Farm Products subindustry, Fujian Aonong Biological Technology Grouporp's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Aonong Biological Technology Grouporp Forward PE Ratio vs Consumer Packaged Goods Industry
Fujian Aonong Biological Technology Grouporp Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Fujian Aonong Biological Technology Grouporp (SHSE:603363) has a Forward PE Ratio of 0.00 as of Sep. 10, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors. According to the industry distribution chart, Fujian Aonong Biological Technology Grouporp ranks #999999 out of 759 companies in the Consumer Packaged Goods industry.
Is Fujian Aonong Biological Technology Grouporp's Forward PE Ratio too high?
Fujian Aonong Biological Technology Grouporp's current Forward PE Ratio is 0.00. Based on the distribution chart, Fujian Aonong Biological Technology Grouporp ranks #999999 out of 759 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Fujian Aonong Biological Technology Grouporp has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fujian Aonong Biological Technology Grouporp's Forward PE Ratio compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Fujian Aonong Biological Technology Grouporp ranks #999999 out of 759 companies for Forward PE Ratio. This places Fujian Aonong Biological Technology Grouporp in the lower half of its industry. The industry median Forward PE Ratio is 12.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Consumer Packaged Goods company?
The median Forward PE Ratio among Consumer Packaged Goods companies is 12.86, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Fujian Aonong Biological Technology Grouporp and its competitors. For the Consumer Packaged Goods industry, the median Forward PE Ratio is 12.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Aonong Biological Technology Grouporp's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Aonong Biological Technology Grouporp stock overvalued right now?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp (SHSE:603363) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.34, compared to a current price of ¥3.12 — trading 132.8% above its estimated fair value. The current Forward PE Ratio is 0.00. Fujian Aonong Biological Technology Grouporp's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Fujian Aonong Biological Technology Grouporp (SHSE:603363), the current Forward PE Ratio is 0.00 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fujian Aonong Biological Technology Grouporp (SHSE:603363) Overvalued in 2026?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp stock appears to be overvalued.
The current stock price of ¥3.12 is trading 132.8% above its estimated GF Value™ of ¥1.34.
GuruFocus considers Fujian Aonong Biological Technology Grouporp to be Significantly Overvalued.
Key valuation signals for SHSE:603363:
Forward PE Ratio: 0.00
GF Value™: ¥1.34 vs. price of ¥3.12 (132.8% above fair value)
No single metric tells the full story. See the SHSE:603363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fujian Aonong Biological Technology Group Incorp Ltd is an agricultural and animal husbandry enterprise in China. The principal business activities of the company include feed-oriented service, animal protection, pig raising, and raw material trade. In addition, the company's insurance business mainly relies on the feed marketing system throughout the country to provide downstream farmers with relevant products for disease prevention and control.
30GF Score
Get the complete analysis for SHSE:603363
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603363 has been successfully added to your 
